SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: UPLOAD
Document Type: TEXT-EXTRACT
Date Filed: 2024-07-26
Accession Number: 0000000000-24-008478
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000000000024008478/filename2.txt

Chunk 0 of 1
Word Count: 1075
Character Count: 6640

Document Content:

July 25, 2024

Jack Ross
Chief Executive Officer
Synergy CHC Corp.
865 Spring Street
Westbrook, ME 04092

Re: Synergy CHC Corp.
Registration Statement on Form S-1
Filed June 28, 2024
File No. 333-280556
Dear Jack Ross:

We have reviewed your registration statement and have the following
comments.

Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe a comment applies to your facts
and circumstances
or do not believe an amendment is appropriate, please tell us why in your
response.

After reviewing any amendment to your registration statement and the
information you
provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1 filed June 28, 2024
Cover Page

1. With reference to your disclosure on page 73, please revise to indicate
whether your
"principal stockholders" are your officers and directors or a different
group.
Overview, page 1

2. Please revise the second paragraph to avoid the implication that you
have paid off this
debt and that you are no longer highly levered.
3. Please revise to explain the term SKU at first use.
4. Please revise the fifth paragraph of the section to highlight the
working capital deficit that
is disclosed on page F-12.
5. Please revise to highlight your debt obligations to Knight as well as
the nature of your
relationship with this party. With reference to the disclosure on pages
F-20 and F-21,
disclose that Knight now must approve your operating budgets. Also,
explain, as
July 25, 2024
Page 2

applicable, whether the June 2024 amendment to your Loan Agreement is a
reason that
you are conducting this public offering at this time.
Our Brands, page 1

6. Please revise to disclose when the Texas trial was conducted and the
number of clubs.
7. We note your disclosure concerning Zion Research and Euromonitor. Revise
to disclose
when these market assessments and projections were made and the relevant
timeframe for
the 3-year CAGR figure. Also, please tell us whether you commissioned
any of the third-
party reports or data cited in the prospectus.
8. In light of your disclosures at the bottom of page 2, the six non-core
brands do not appear
to be key aspects of the offering that should be highlighted in the
Summary presentation.
Please revise or advise. Refer to the Instruction to Regulation S-K,
Item 503(a). With
reference to the disclosure on page 55, also tell us, and revise where
applicable, to
indicate: (i) whether the Neuragen and UrgentRx products will be
regulated as
pharmaceutical drugs as opposed to supplements, and (ii) what your basis
is for
identifying Neuragen as an "effective" treatment.
9. We note your disclosure indicating that the patent provides you with a
competitive
advantage. With reference to your disclosure on page 57, please revise
to provide balance
and context to this disclosure by explaining that the patent expires in
April 2025
Results Backed by Independent Study for FOCUSfactor, page 4

10. Please revise the disclosure in the first paragraph to explain, if true,
that FDA has not
reviewed this study or evaluated these performance claims.
Use of Proceeds, page 29

11. Please revise to explain the amount intended to be allocated to each
purpose. As an
example, disclose the amount intended for advertising. Also,
explain what supporting
organic growth encompasses so it is clear how it differs from
general corporate
purposes.
12. In light of your disclosure on pages F-20 and F-21, please tell us
whether any of the
offering proceeds are intended to repay outstanding debts or obligations
owed to Knight
or Shopify.
13. We refer to your disclosure on page 1 regarding potential near-term
acquisitions of other
businesses. Please provide the disclosures required pursuant to
Instruction 6 of
Regulation S-K, Item 504.
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Results of Operations for the Years Ended December 31, 2023 and December 31,
Revenue, page 36

14. We note that you break out the amount of net revenue for the FOCUSfactor
brand for the
three months ended March 31, 2024 in the Business section on pages 46
and 48. Please
revise your results of operations disclosure to break out the amount of
net revenue by
brand for all periods presented.
July 25, 2024
Page 3
Liquidity and Capital Resources, page 38

15. We note your disclosures indicating that you have $20,000,000 available
for certain future
acquisitions under your credit facility with Knight. Please revise to
disclose whether there
are material limitations to your ability to access this funding. In this
regard, we note that
the June 2024 amendment indicates that Knight must approve your
operating budget and
that Knight is seeking for you to repay $12.4 million from existing
loans in the next two
years.
Liquidity, page 38

16. Please expand your disclosures of short- and long-term borrowings to
state whether you
are in compliance with all of the terms, conditions, and covenants
associated with
your loan agreements.
Management, page 59

17. We note that Jack Ross is also the CEO of two other entities. Please
revise to clarify how
he allocates his time across these three entities.
Certain Relationships and Related Party Transactions, page 71

18. We refer to your disclosure on page 72 concerning your transactions with
BoomBod Ltd.
Please revise to disclose the nature of the expenses and reimbursements.
With reference to
your balance sheet, discuss the timing for repayment of this loan.
General

19. Please supplementally provide us with copies of all written
communications, as defined in
Rule 405 under the Securities Act, that you, or anyone authorized to do
so on your behalf,
present to potential investors in reliance on Section 5(d) of the
Securities Act, whether or
not they retain copies of the communications.

We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.
July 25, 2024
Page 4

Please contact Tracie Mariner at 202-551-3744 or Vanessa Robertson at
you have questions regarding comments on the financial statements and related
matters. Please
contact Tamika Sheppard at 202-551-8346 or Joe McCann at 202-551-6262 with any
other
questions.

Sincerely,

Division of
Corporation Finance
Office of Life
Sciences
cc: Mike Bradshaw